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Geneticists and epidemiologists often observe that certain hereditary
disorders cooccur in individual patients significantly more (or signif-
icantly less) frequently than expected, suggesting there is a genetic
variation that predisposes its bearer to multiple disorders, or that
protects against some disorders while predisposing to others. We
suggest that, by using a large number of phenotypic observations
about multiple disorders and an appropriate statistical model, we can
infer genetic overlaps between phenotypes. Our proof-of-concept
analysis of 1.5 million patient records and 161 disorders indicates that
disease phenotypes form a highly connected network of strong
pairwise correlations. Our modeling approach, under appropriate
assumptions, allows us to estimate from these correlations the size of
putative genetic overlaps. For example, we suggest that autism,
bipolar disorder, and schizophrenia share significant genetic overlaps.
Our disease network hypothesis can be immediately exploited in the
design of genetic mapping approaches that involve joint linkage or
association analyses of multiple seemingly disparate phenotypes.
autism  bipolar disorder  harmful genetic polymorphisms 
schizophrenia  shared genes
In ‘‘simple’’ disorders with proven Mendelian inheritance, asingle-nucleotide aberration in the genome can cause one disease
while protecting against another; one nucleotide substitution can
also manifest in multiple physiological systems. For example, a
single-nucleotide substitution in a human -globin gene (HBB)
triggers in its bearer a drastic change of erythrocyte shape (sickle-
cell anemia) but protects against invasion of the protozoan parasite
(Plasmodium falciparum) that causes malaria. When designing a
mathematical model that describes pairs of disease phenotypes, we
can think of sickle-cell anemia and malaria as competing for the
same nucleotide site in the human genome. In another example, a
single-nucleotide polymorphism in the CFTR gene profoundly
affects the bearer’s digestive, reproductive, and respiratory systems
and causes excessive loss of salt through sweating (a group of
symptoms collectively known as cystic fibrosis). By analogy with our
metaphor of phenotype competition for genes, wewill say that these
disparate phenotypic manifestations in cystic fibrosis cooperatively
share the same nucleotide substitution (i.e., the substitution has a
pleiotropic effect).
Does this logic of competitive or pleiotropic genetic polymor-
phisms extend to human disorders that have more complex (and
largely unknown) genetics? We think it does. Here, we suggest a
method for assessing such overlaps between complex phenotypes (a
reframed comorbidity analysis), then demonstrate its application to
a set of 161 disorders described in 1.5 million patient records from
a clinical database at the Columbia University Medical Center.
We selected disorders that represent a broad spectrum of mal-
adies, from common to rare, affecting diverse physiological systems,
yet we also placed special emphasis on neurological phenotypes
[Fig. 1 gives a complete account of phenotypes that we analyzed; we
provide information on symptoms and patient statistics for each
phenotype in supporting information (SI)]. Our choice of pheno-
types reflect a view that the etiology of every human malady, even
one as recently encountered and as clearly linked to an environ-
mental cause as AIDS, includes a significant component of hered-
itary predisposition and/or resistance. For example, a series of
recent studies showed that a significant proportion of people are
partially or completely resistant to HIV infection, whereas other
people have a predisposition to rapid AIDS progression once HIV
infection has occurred (1).
Results and Discussion
Outline of Our Approach.Wedeveloped aprobabilisticmodel linking
the unobserved genetic variation in human genomes to the ob-
served succession of healthy and disease phenotypes in individual
humans. Before formulating the model’s assumptions and explain-
ing details of its implementation, let us briefly outline its main
components (Fig. 2B). In our description, when we consider a pair
of disorders (D1 andD2), we model an individual’s phenotype at or
before a certain age (Fig. 2C). A person is born with (or without)
a set of disease-predisposing variations (represented by random
variables k1, k2, and k12 in Fig. 2B); these variations determine the
probability that the person eventually will be diagnosed with the
disease (age-integrated phenotype; see Fig. 2 B and C). Given that
the age-integrated phenotype involves disease Di and the individ-
ual’s life span, the individual can manifest symptoms of Di at any
time during his/her lifetime with probability specified by the time-
of-onset function specific to this disease and possibly by the
individual’s ethnicity and gender (see Fig. 2 B and C). We need to
take into account the time course of each disorder to ‘‘subtract’’ all
correlations between disorder pairs that are merely due to a
commonality or a difference in their onset times. Without this age
adjustment, an early-onset disease, such as autism, and a late-onset
disease, such as Parkinson’s disease, would misleadingly appear as
negatively correlated.
To implement the model, we need a set of assumptions making
our computation tractable.
Assumptions. Environmental factors (such as physiological stress,
diet, lifestyle, and exposure to pathogens) affect human phenotypes
through the action of numerous molecules that are produced,
distributed within cells and tissues, and used according to gene-
encoded scripts. Therefore, our first assumption here is that, if the
same environmental effect triggers two (or more) different mala-
dies, it typically does so through molecular mechanisms that are
common between these two maladies. Although this assumption is
likely to be violated for some pairs of disorders, it is a reasonable
starting point for the model. This assumption allows us to develop
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a probabilisticmodel linking the unobserved genetic variation to the
observed phenotypes. We take into account environmental influ-
ence via a data-derived function that approximates the classical
age-of-onset distribution, the cumulative probability that a disease
manifests itself before or at any given age and given that the person
will eventually get the disease (see Fig. 1). Note that these disease-
specific functions are highly informative on their own and would
merit careful examination. For example, allergic rhinitis, breast
cancer, and especially viral infections have markedly different
patterns of incidence in males and females; the function shapes are
notably variable across disorders.
Our second assumption is that, for each phenotype pair (D1 and
D2), the whole human genome can be divided into four disjoint sets
of nucleotide sites (Fig. 2A). One set (S0) comprises nucleotide sites
that can affect neither of the two phenotypes, regardless of each
site’s state. Sites within another set (S12) can affect both phenotypes
simultaneously, either via a competitive or a cooperative mecha-
nism. The remaining two site sets have the potential of predisposing
the bearer exclusively to either phenotypeD1 (set S1) orD2 (set S2)
(see Fig. 2A). Depending on our choice of phenotypes, some of
these four site sets may be empty.
Our third assumption involves a spectrum of hypothetical mech-
anisms that connect genetic variation within the four sets of
nucleotide sites to the disease phenotype (genetic penetrance). All
mechanisms we consider here have in common an intuitive prop-
erty that, the larger the number of genetic aberrations within the
disease-predisposing set of sites, the more likely the disease phe-
notype will manifest itself. We consider here two families of
genetic-penetrance functions: sharp and soft threshold. With a
sharp-threshold function, the bearer must have at least  disease-
related polymorphisms (where  is a positive integer) if she/he is
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Fig. 1. Probability that a person manifests symptoms of a disorder before or at age t (given that she/he will be eventually diagnosed with the disease Di [P(Ti
 t  Ti , e, g; )  1  Fi(t  e, g; )]) for the 161 disorders we consider in this study. Each graph has the same format: the x axis represents the individual’s
age (bounded by 0 and 100 years); the y axis represents the probability that the individual is diagnosed with the specific disorder before or at age t (bounded
by 0 and 1). The red and blue curves represent data for female and male patients, respectively. The numbers shown in red and blue indicate the number of records
describing female and male patients, respectively, that we used to estimate each disorder-specific curve.






obtain the classic multilocus heterogeneity model, whereas larger
values of the parameter represent more complex epistatic gene
interaction models (2). With a soft-threshold function (see SI), the
relationship between the number of deleterious polymorphisms and
the time-integrated phenotype is more complicated: the likelihood
that an individual’s age-integrated phenotype will include a specific
Fig. 2. Model assumptions, definitions,
and results of the following analysis. (A–C)
The structure and main concepts associated
with our model, which describes a pair of
disorders, D1 and D2. (A) We partition all
nucleotide sites in the human genome into
four disjoint sets, S0, S1, S2, and S12. (B)
Structure of our probabilistic model. Ar-
rows indicate the sequence of probabilistic
conditioning in computation of the likeli-
hood under our model (see Methods). (C)
Time course of phenotype change as the
person ages, as described by our model. In
this example, the person starts as a healthy
individual at t1 (phenotype 0); at time
points t2 and t3, the person displays D1 and
D2, respectively, so (t2)  1, and (t3) 
12. (D–G) Two hypothetical models of
gene-disease mappings (D and E) and esti-
mates of the proportion of autism-specific
nucleotide sites that autism ‘‘shares’’ with
schizophrenia (F) and bipolar disorder (G).
(D) A simple hypothetical model, probably
most appropriate for Mendelian disorders,
where different disorders are mapped to
disjoint sets of genes, with a deterministic
relationship between genetic polymor-
phism and phenotype. (E) A more compli-
cated hypothetical model, probably appli-
cable to common (highly prevalent)
disorders, where multiple genes determine
predisposition to a disease in a probabilistic
and combinatorial fashion. (F) Posterior dis-
tribution for estimate of relative size of
genetic overlap of autism with schizophre-
nia under three different models of genetic
penetrance (we used an uninformative
prior distribution). Parameter  represents
the smallest number of deleterious poly-
morphisms in disease-specific nucleotide
sites required for the disease phenotype to
manifest itself. (G) Similar estimate of ge-
netic overlap between autism and bipolar
disorder, relative to the genetic basis of
autism. (H–J) Significant correlations be-
tween pairs of disorders. In each of the four
plots, we compare one disorder (in the cen-
ter of the plot) against the other 160 disor-
ders that we selected for this study. The
color of the arc, with corresponding num-
ber, represents the value of the  statistic.
The warm-colored edges have the highest
 values, and those in the colder part of the
color spectrum represent smaller  values.
All values of8 are highly significant. The
white and turquoise labels indicate disor-
ders that are positively and negatively cor-
related, respectively, with the disorder in
the center of the subplot. The size of a node
indicates the number of the disorder-
specific patient records in our data set (note
that the node scale is different for different
plots). (H) Autism, data for male patients
only (see SI for analogous analyses of fe-
male patients and joint analysis of both
male and female patients). (I and J) Bipolar
disorder and schizophrenia, joint analyses
of both genders.
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disorder at the end of the individual’s life is nonzero for any number
of the disease-related variations in her/his genome but grows
quickly with an increase in the number of deleterious variations
related to the disorder (see SI for details).
Competing Models. In our data analysis, for every pair of disorders,
we choose one of three competing models (hypotheses): (i) the
disorders are uncorrelated (which we interpret as a lack of a genetic
overlap), (ii) the disorders are significantly negatively correlated
(whichwe interpret as a genetic overlap via competition), or (iii) the
disorders are significantly positively correlated (genetic overlap via
cooperation; seeMethods). The cooperative model is slightly more
general than the standard genetic pleiotropy model. The two
models are identical when two phenotypes are caused by exactly the
same set of genetic polymorphisms; however, unlike the pleiotropy
model, the cooperation model allows each phenotype (in addition
to the shared polymorphisms) to be associated with a pool of
genetic polymorphisms that does not affect the other phenotype.
The independence model is a special case of both overlap models,
so we can represent results of our analysis with the two log-
likelihood-ratio statistics (), comparing both overlapmodels to the
model of independence (Figs. 2 H–J and 3). Furthermore, our
parametric model provides an estimate of the size of the hypothet-
ical genetic overlap (Fig. 2E and SI).
Correlations and Overlaps. Our analysis of genetic overlap reveals
numerous correlations among disorders, many of which are well
established (e.g., see refs. 3–8), whereas other correlations appear
previously undescribed.
It is not surprising that autism is strongly correlated with perva-
sive developmental disorders and fragile X syndrome (Fig. 2H),
because autism is included (along with several other disorders) in
the formal definition of pervasive developmental disorders, and
fragile X syndrome has autism as one of its manifestations. How-
ever, it is less obvious why autism, which typically manifests before
the affected child is 3 years old, has a strong positive correlation
with a number of neurological disorders, some of which have a
late-age onset (ordered by decreasing statistical significance; see
also Fig. 2H): attention deficit, epilepsy, cerebral palsy, depression,
schizophrenia, bipolar disorder, neurofibromatosis, Parkinson’s
disease, and migraine. Our estimated significant overlap between
autism and tuberculosis may indicate that both diseases are asso-
ciated with genetic changes weakening the immune system.
Another group of phenotypes that overlaps with the most highly
prevalent neurological disorders comprises various bacterial, viral,
and protozoan infections. In the case of autism, the most strongly
positively correlated phenotypes of this group include viral infec-
tions of the central nervous system (such as viral encephalitis),
tuberculosis, viral infections of other systems, and staphylococcal
and Helicobacter pylori infections (phenotypes are sorted here by
decreasing significance of correlation). The third group of pheno-
types, comorbid with autism and with many highly prevalent
neurological disorders, includes allergies and autoimmune disor-
ders, such as allergic rhinitis. Schizophrenia and bipolar disorder
are positively correlated with many additional disorders of this
group, including diabetes, rheumatoid arthritis, and psoriasis (see
Figs. 2 I and J and 3). The fourth group of autism-correlated
disorders includes both benign andmalignant neoplasms. Autism is
also comorbid with Kawasaki’s disease [a relatively rare phenotype
whose etiology is ill-understood and that probably relies on an
unknown pathogen; similar to autism, it affects male individuals
significantly more frequently than females (see SI)], acanthosis
Fig. 3. Significant correlations (that we
interpret as genetic overlap) among three
neurodevelopmental disorders (autism, bi-
polar disorder, and schizophrenia; corre-
sponding nodes are shown in yellow) and
all other disorders in our data set (blue
nodes). The volume of each sphere (dis-
ease) is proportional to the number of pa-
tient records annotated with the corre-
sponding phenotype, as explained in the
key. The arcs represent significant correla-
tions among phenotypes, with negative
correlations shown in blue and positive cor-
relations shown in red. Thicker arcs repre-
sent stronger correlations; see key.






nigricans, and aberrations of carbohydrate metabolism. Similar
groups of highly correlated phenotypes are visible in our analyses
of schizophrenia and bipolar disorder (see Fig. 2 I and J), with the
important addition that female breast cancer shows strong negative
correlations with both schizophrenia and bipolar disorder (unlike
other malignancies, including male breast cancer; see SI). This
negative correlation is highly significant even when only female
patients are analyzed (see SI). The negative correlation may
indicate in the framework of our model a competition for genes in
the cell cycle/cell death regulation: both schizophrenia and bipolar
disorder under this explanation are associated with genetic poly-
morphisms that increase the probability of abnormal cell death in
some tissues, whereas breast cancer is linked to (only partially
known) genetic variation leading to an increased probability of
abnormal cell proliferation. Although the competitive genetic
overlap between bipolar disorder and female breast cancer has not
been reported, there is recent indirect evidence that supports it: a
well established breast cancer-treatment drug, tamoxifen, was
recently discovered to be effective in treating symptoms of bipolar
disorder (9).
We show a composite representation of correlations (interpreted
as genetic overlaps) for autism, bipolar disorder, and schizophrenia
(yellow spheres) and the rest of 158 disorders (blue spheres) in Fig.
3. All blue spheres have one, two, or three incoming arcs, indicating
they correlate significantly with one, two, or all three of the
yellow-sphere disorders. For example, acanthosis nigricans and
cerebral palsy are positively correlated with every member of the
yellow-sphere disease triplet. Female breast cancer is significantly
negatively correlated with bipolar disorder and schizophrenia (blue
arcs) but shows no significant correlation with autism. Neurofibro-
matosis is significantly positively correlated with autism and bipolar
disorder (red arcs) but not with schizophrenia. Aortic aneurysm is
negatively correlated with schizophrenia but is independent of
autism and bipolar disorder.
Proportion of Autism-Predisposing Polymorphisms That Also Contrib-
ute to Schizophrenia or Bipolar Disorder. So long as our model is
designed for estimating the mean number of disease-related poly-
morphisms (per a randomly sampled human genome) in disease-
specific site sets and in genetic overlap among disease pairs, we can
use such estimates to assess the proportion of autism-predisposing
variation that is sharedwith bipolar disorder andwith schizophrenia
(see Fig. 2 F and G).
Despite the fact that the absolute estimates of the expected
number of disease-related polymorphisms are different under
different models of genetic penetrance (see the model description
and tables in SI), the proportion of the polymorphisms that autism
shares with bipolar disorder and schizophrenia is consistent across
different models (Fig. 2 F and G): we estimate that 	20–60% of
autism-predisposing variations also predispose the bearer to bipolar
disorder, and 20–75% of autism-predisposing variations also pre-
dispose the bearer to schizophrenia. It is therefore extremely likely
that there is a three-way positive correlation among autism, bipolar
disorder, and schizophrenia, a correlation that probably arises from
a genetic variation that predisposes to all three disorders.
Corollaries. Our analysis suggests that, instead of following the
familiar model of ‘‘uniquemalady–unique (disjoint with others) set
of broken genes’’ applicable tomostMendelian disorders (Fig. 2D),
most complex phenotypes are probably rooted in genetic variation
that is significantly shared (in either a competitive or cooperative
manner) by multiple disease phenotypes (Fig. 2E).
Phenotypes of non-Mendelian disorders are often defined with
a considerable degree of fuzziness, especially those that are neu-
rological: it is not uncommon to define a neuropsychiatric disease
phenotype as comprising, for example, at least five of a list of 10
symptoms (4). This fuzziness arises because, in many cases, the
observed disease is a heterogeneous collection ofmultiplemaladies
that have partially similar symptoms and potentially different
genetic causes. However, these genetically heterogeneous maladies
are combined because of the history of disease identification and
the incompleteness of our knowledge about the disease causes.
Our interpretation of genetic overlap among pairs of disorders
does not exclude the possibility that one disorder can cause the
other. For example, it is possible that comorbidity of autism (or
schizophrenia, or bipolar disorder)with infectious and autoimmune
maladies indicates that the neurodevelopmental disorder can be
triggered by different developmental insults, including viral or
bacterial infection, or an autoimmune disease launched by a benign
allergen. Another possibility is that the same molecular features
that make a child more susceptible to infection or to autoimmune
attack have a pleiotropic effect on brain development and function.
Our analysis has immediate practical implications for the design
of gene-mapping studies that examine complex phenotypes. Imag-
ine that we can study a set of families (pedigrees) whose members
are affected by multiple disorders (for example, autism, bipolar
disorder, schizophrenia, diabetes, and psoriasis). If we have reasons
to believe that these disorders overlap in terms of disease-
predisposing genetic variation, to extract maximum information
from available data, we might be able to design genetic linkage or
association strategies that analyze multiple complex disorders
jointly. Furthermore, by selecting different sets of seemingly dis-
parate disorders, we might be able to examine systematically the
genetic background of a wide spectrum of complex phenotypes. In
addition, we hope that the estimated disease overlaps will be useful
in defining sharper (more specific) phenotypes that are also more
genetically homogeneous.
Methods
Data.Our input data comprise anonymized statistics about patients
in the Columbia University Medical Center clinical database (1.5
million records). This database was designed for pragmatic pur-
poses (such as billing) rather than for basic research; thus, in this
study, we used a predefined data representation not specifically
optimized for our purposes (see SI). With respect to the two
diseases,D1 andD2, the ith patient (H in the notationHi stands for
human) is described with the following pentaplet of variables.

Hi Ai, Gi, Ei, O1.i, O2.ii1....,N, [1]
where N is the total number of patients in the database, Ai is the
patient’s age, Gi is the patient’s gender, Ei is his/her ethnicity, and
O1,i and O2,i are the patient’s ages at the time she/he was first
diagnosed with diseases D1 and D2, respectively. For the sake of
encoding simplicity, we setOk,i to infinity () for patients who were
never diagnosed with disease Dk.
The ethnicity, Ei, attributed to the ith patient in our data can have
one of the following codes: A, B, D, E, H, I, M, N, L, O, P, U, W,
or X. A table in SI provides the key to these codes.
Variable Gi takes values F (female),M (male), O (other, usually
indicating an ambiguity/difficulty in gender assignment), and U
(unknown, usually indicating missing data).
Models. Let us focus on two human diseases, D1 and D2, each of
which has a distinct hereditary component.We candivide thewhole
genome into four disjoint sets of nucleotide sites, S0, S1, S2, and S12
(see Fig. 2A). The first set, S0, comprises genomic sites that have no
potential to contribute to either of the two diseases. The second and
the third sets of sites, S1 and S2, include genomic loci that, when they
harbor deleterious polymorphisms, predispose the polymorphisms’
bearers to D1 and D2, respectively (see Fig. 2A). Finally, the fourth
set of sites, S12, involves portions of the genome that predispose an
individual who bears mutations in them to both D1 and D2
simultaneously. Although here we focus on point mutations, our
approach can be extended to other types of genetic polymorphism,
such as insertions, deletions, inversions, and translocations.
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Phenotypes. We define the following four phenotypes with
respect to diseases D1 and D2: 1, 2, 12, and 0 correspond
to ‘‘affected by disease D1 but not by disease D2,’’ ‘‘affected by
disease D2 but not by disease D1,’’ ‘‘affected by both diseases
D1 and D2,’’ and ‘‘affected by neither disease D1 nor D2,’’
respectively.
Genotypes: Probability of Gi  {ki,1, ki,2, ki,12}. We denote the total
number of deleterious polymorphisms that fall into S1, S2, and S12
for individual i with a triplet of random variables {ki,1, ki,2, ki,12}. In
our model, these three variables completely describe the individu-
al’s genotype, Gi, with respect to diseases D1 and D2. We assume
that the random variables ki,1, ki,2, and ki,12 independently follow
Poisson distributions (10) with rates 1, 2, and 12, respectively. If
a disease-related nucleotide site set Sk is small, as in the case of
sickle-cell anemia (just two sites), we can assume that the observed
number of disease-relevant polymorphisms per genome follows a
binomial distribution instead of a Poisson distribution (see SI).
Probability of () given Gi  {ki,1, ki,2, ki,12} (penetrance function). We
use the notation () to denote an individual’s phenotype with
respect to diseases D1 and D2 at the end of his/her life (eventual or
age-integrated phenotype; see Fig. 2B). We consider here two
definitions of the penetrance function. The first definition postu-
lates that disease D1 manifests itself only if the number of delete-
rious variations in S1 and S12, ki,1  ki,12 is equal or greater than a
threshold, 1 (similarly, D2 develops eventually if ki,2  ki,12  2).
The second definition postulates that the threshold value itself is a
random variable, so that the probability of developing a disease
gradually increases with the number of deleterious polymorphisms
(see SI for details).
Probability of(t) given().Weuse the notation(t) to indicate an
individual’s phenotype at or before age t. Let T1 and T2 be the ages
at onset (or first diagnosis) of diseases D1 and D2, respectively.
(t)1 is then equivalent to {T1 t, T2 t}. Thus, the likelihood
of the two-disease phenotype status can be studied using the joint
failure time model (11) for T1 and T2, based on the genetic factors
and covariates such as age and gender.We then define the following
conditional distributions for T1 and T2,
Fktke, g;  PTk tkTk	 ,e, g; , [2]
where k  1, 2. Note that we can estimate Fk(tk  e, g; ) directly
from our data (estimates of 1 Fk(tk  e, g;) are shown in Fig. 1).
Finally, we define the probability of (t) given () in terms of
probabilities Fk(tk  e, g; ), as shown in Table 1.
Two genetic overlap models: Cooperation and competition. In the co-
operation (generalized pleiotropy) model, the overlap genes can
simultaneously contribute to both diseases, whereas in the compe-
titionmodel, the overlapped genes can contribute to only one of the
diseases (the choice is made stochastically with probability specific
to each pair of diseases; see SI).
Likelihood and Likelihood Ratio Test. To compute a likelihood value
for data representing the ith patient, we need to sum the probability
of the observed phenotype [given ki,1, ki,2, ki,12, and ()] over all
admissible values of ki,1, ki,2, ki,12 (ki,j 0, 1, . . . , ), and () (see
SI for description of an efficient computation of this value). If we
assume that the vector of parameters, , is the same for all values
of e (ethnicity) and g (gender), then the likelihood function is just
a product (over all patients) of probabilities of the observed
phenotypes given common parameter values (see SI). (Alterna-
tively, we subdivide the data by ethnicity and gender and estimate
a separate set of parameters for each data subset.)
At its heart, our analysis is a model selection problem. First, we
have two versions of the same model where two disorders have an
arbitrarily large genetic overlap (via either a cooperation or com-
petition scenario). Second, we have a simpler model that is nested
in both former models, where the two disorders are genetically
independent. Put differently, the model where two disorders, D1
andD2, are genetically independent (the genetic overlap, nucleotide
set S12, is empty [12 0]) is a special case of the two models where
the same two disorders are either genetically overlapping or inde-
pendent (S12  [12 0] or S12  [12 0]). Therefore, we can
use a standard log-likelihood ratio statistic, , for nested models.
This  statistic asymptotically (as the sample size grows) follows a

2 distribution with the number of degrees of freedom equal to the
difference in the number of parameters between the twomodels (1,
in our case) (12).
In the presence of a statistical signal, we can distinguish among
the three models (independence, cooperation, and competition) by
computing two statistics: cooperation and competition.
Availability.Detailed information on estimated disease overlaps for
all pairs of disorders mentioned in this study is available as SI.
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Table 1. Conditional probability of the age-t phenotype [(t)] given the ultimate
phenotype [()]
P((t)(), e, g; )
()
0 1 2 12
0 1 F1(te, g; ) F2(te, g; ) F1(te, g; ) F2(te, g; )
(t) 1 0 1  F1(te, g; ) 0 (1  F1(te, g; ))F2(te, g; )
2 0 0 1  F2(te, g; ) F1(te, g; )(1  F2(te, g; ))
12 0 0 0 (1  F1(te, g; ))(1  F2(te, g; ))
Total 1 1 1 1
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